FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

仅供研究使用。 完整免责声明 →

研究/论文
返回研究图书馆
PubMedReview

Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.

Kal Satadeepa, Mahata Sumana, Jati Suborno, Mahata Sushil K
Peptides2024DOI: 10.1016/j.peptides.2023.171147
HumaninMOTS-cSHLP1-6

质量评分

7/10

引用次数

0

主题

非人类

Peptide Contacts分析

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of Humanin, MOTS-c, SHLP1-6 in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the Humanin, MOTS-c, SHLP1-6 evidence base. The findings here should inform future clinical trial design.

关键发现

The review highlights the antidiabetic functions of mitochondrial-derived peptides (MDPs) such as Humanin, MOTS-c, and SHLP1-6 in managing Type 1 diabetes, Type 2 diabetes, and gestational diabetes. It also discusses the evolutionary conservation of MDPs.

局限性

As a review paper, it relies on existing literature and does not present new experimental data or clinical trials to validate its claims about MDP functions.

如何解读这项研究

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts分析

Highlight the current state of knowledge on mitochondrial-derived peptides (MDPs) and their potential as therapeutic agents in diabetes management, emphasizing evolutionary perspectives.

HumaninMOTS-cSHLP1-6

Mitochondrial-Derived Peptides: A New Frontier in Diabetes Treatment?

Published: May 16, 2026 | Source: Peptides (2024) | Category: Humanin, MOTS-c, SHLP1-6

Overview

Recent research has shed light on a novel class of peptides called mitochondrial-derived peptides (MDPs), which are encoded by short open-reading frames in the mitochondria's DNA. These MDPs—Humanin (HN), MOTS-c, and small Humanin-like peptides (SHLP1-6)—show promise as potential therapeutic agents for managing diabetes, particularly Type 1, Type 2, and gestational diabetes. Understanding their evolutionary conservation provides insights into their biological significance.

Study Background

Before this study, MDPs were known to play roles in various cellular processes but their specific functions in diabetes management remained unclear. Researchers sought to explore the antidiabetic properties of these peptides and understand why they have been conserved throughout evolution despite being encoded by a small portion of mitochondrial DNA.

What the Research Found

The review highlights that MDPs, such as Humanin (HN), MOTS-c, and SHLP1-6, play crucial roles in regulating glucose metabolism and insulin sensitivity. For instance, HN has been shown to protect pancreatic beta cells from oxidative stress-induced apoptosis, which is a significant factor in the progression of Type 1 diabetes. Similarly, MOTS-c enhances insulin secretion and improves glucose tolerance in animal models of Type 2 diabetes.

SHLP peptides also exhibit antidiabetic properties but their mechanisms are less understood compared to HN and MOTS-c. The review emphasizes that these peptides use unique genetic codes different from those used by nuclear DNA, which underscores the complexity and specificity of mitochondrial gene expression.

What This Means for Peptide Users

While this research provides a strong theoretical framework for the potential therapeutic benefits of MDPs in diabetes management, it does not yet translate into clinical applications. Further studies are needed to validate these findings through clinical trials and to determine safe dosages and delivery methods for human use.

Limitations and Caveats

As a review paper, this study relies heavily on existing literature rather than presenting new experimental data or clinical trial results. Consequently, the claims about MDP functions in diabetes management need further validation through rigorous scientific investigation. Additionally, the evolutionary conservation of these peptides does not necessarily imply their therapeutic efficacy; more research is required to confirm this.

How This Compares to Previous Research

Previous studies have also highlighted the potential roles of MDPs in various diseases, including neurodegenerative disorders and cancer. However, this review specifically focuses on diabetes management and evolutionary perspectives, providing a unique angle that complements existing knowledge.

Our Analysis

PeptideVault views this research as an important step towards understanding the multifaceted roles of mitochondrial-derived peptides. The paper effectively synthesizes current literature to highlight potential therapeutic avenues but acknowledges the need for further experimental validation. Its emphasis on evolutionary conservation adds depth to our understanding of these peptides' biological significance, though it does not directly translate into immediate clinical applications.

Key Takeaways

  • Evolutionary Conservation: MDPs have been conserved across species due to their critical roles in cellular processes.
  • Antidiabetic Potential: Humanin (HN), MOTS-c, and SHLP1-6 show promise in managing Type 1, Type 2, and gestational diabetes but require further clinical validation.
  • Unique Genetic Codes: MDPs use distinct genetic codes compared to nuclear DNA, highlighting the complexity of mitochondrial gene expression.

Original Source

Citation: Kal Satadeepa, Mahata Sumana, Jati Suborno et al. (2024). Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.. Peptides. DOI: 10.1016/j.peptides.2023.171147

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队撰写,旨在使复杂的发现对肽类社区易于理解。鼓励读者查阅源论文以获取完整的方法和数据。 欲了解Humanin更多信息,请参阅我们的 研究指南.

引用

Kal Satadeepa, Mahata Sumana, Jati Suborno et al.. (2024). Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives.. Peptides. https://doi.org/10.1016/j.peptides.2023.171147

在PubMed查看全文

相关论文

进一步探索

此内容基于同行评审研究仅用于教育目的。不构成医疗建议。在使用任何肽类疗法前,请咨询合格的医疗服务提供者。